Core Insights - The latest round of national centralized drug procurement in China has successfully awarded contracts for 55 drugs, with 453 products from 272 companies qualifying for selection, expanding the total number of covered drugs to 490 [1] Group 1: Company Participation - Kelun Pharmaceutical and Yuandong Biological, two listed pharmaceutical companies from Chengdu, announced a total of 14 products that are likely to be selected in the recent procurement round [1] - Kelun Pharmaceutical reported that it and its subsidiaries participated in the 11th national drug procurement, with 12 products likely to be selected across various treatment areas including liver disease, oncology, and mental health [3][4] Group 2: Product Details - The 12 products from Kelun Pharmaceutical cover a range of diseases, including chronic liver disease, ovarian cancer, depression, and chronic obstructive pulmonary disease, showcasing the company's diverse product portfolio [3] - The proposed winning prices for Kelun's products vary significantly, from 2.11 yuan per bag for a specific injection to 195.37 yuan per box for an oncology drug, indicating a wide range of medication price points [3] Group 3: Financial Impact - For the 12 products proposed for selection by Kelun, most had zero sales revenue prior to this procurement, with only a few products generating minimal revenue in 2023 or 2024 [3] - Yuandong Biological announced that its selected products, including a specific injection and a tablet, contributed to a small percentage of the company's total revenue for the first nine months of 2025 [4] Group 4: R&D Investment - Yuandong Biological has maintained an average R&D investment of over 20% of its revenue in the past three years, leading to a high conversion efficiency with at least 10 new formulations approved for market each year [4]

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced its participation in the 11th national centralized drug procurement, with two products, Adrenaline Hydrochloride Injection and Beclomethasone Sodium Tablets, expected to be selected for procurement [1][2]. Group 1: Product Information - The two products proposed for selection are Adrenaline Hydrochloride Injection, which received its drug registration certificate in May 2022, and Beclomethasone Sodium Tablets, which received its certificate in May 2024 [2]. - Sales revenue for Beclomethasone Sodium Tablets from January to September 2025 was 1.2194 million, accounting for 0.12% of total revenue, while Adrenaline Hydrochloride Injection generated 21.7564 million, representing 2.13% of total revenue during the same period [2]. Group 2: Impact on Company - The centralized procurement is expected to prioritize the selected drugs in medical institutions, ensuring the completion of agreed procurement volumes. The selected products are anticipated to start execution in the first quarter of 2026, with no impact on the company's performance for the fiscal year 2025 [2]. - The selected procurement prices are expected to decrease compared to original sales prices, which may enhance drug accessibility [2]. Group 3: Company Strategy and R&D - The company has a diverse product matrix, with an average of over 20% of revenue invested in R&D over the past three years, leading to a high conversion rate of new products [3]. - The company has been actively increasing its portfolio of special narcotic drugs and expects new approved products to contribute to revenue growth. It is also accelerating its innovation transformation, focusing on core innovation pipelines such as molecular glue and PROTAC [3].

Core Viewpoint - Yuan Dong Bio (688513) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with two products, namely, Dexmedetomidine Hydrochloride Injection and Beraprost Sodium Tablets, expected to be selected for this procurement [1] Group 1 - The company participated in the centralized procurement bidding on October 27, 2025 [1] - The products involved in the bidding are Dexmedetomidine Hydrochloride Injection and Beraprost Sodium Tablets [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with two products, namely, Dexmedetomidine Hydrochloride Injection and Beraprost Sodium Tablets, expected to be selected for this procurement [1] Group 1 - The company participated in the bidding for the 11th batch of national centralized drug procurement on October 27, 2025 [1] - The products involved in the procurement are Dexmedetomidine Hydrochloride Injection and Beraprost Sodium Tablets [1]

证券代码：688513 证券简称：苑东生物 公告编号：2025-077 成都苑东生物制药股份有限公司 关于自愿披露公司参与全国药品集中采购拟中选的公告 | 序号 | 拟中选品 | | | 适应症 | 规格包 | 计价 | 拟中选价 | | 采购周期 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 种 | | | | 装 | 单位 | 格（元） | | | | | | 盐 酸 | 去 | 氧 | 用于治疗麻醉时血管扩张 | 5ml： | | | 至 | 2028 | 年 | | 1 | 肾 上 | 腺 | 素 | 引起的临床低血压。 | 0.5mg*1 | 支 | 1.35 | 12 | 月 31 | 日 | | | 注射液 | | | | 支 | | | | | | | 2 | 贝 前 | 列 | 素 | 用于改善慢性动脉闭塞性 疾病引起的溃疡、间歇性 | 20ug*30 | 盒 | 13.98 | 至 | 2028 | 年 | | | 钠片 | | | 跛行、疼痛和冷感等症状。 | 盒 片*1 | | | ...

Group 1 - The core point of the news is that Yuandong Biopharmaceuticals experienced a stock price increase of 5.47%, reaching 55.30 CNY per share, with a trading volume of 150 million CNY and a turnover rate of 1.58%, resulting in a total market capitalization of 9.762 billion CNY [1] - Yuandong Biopharmaceuticals, established on June 1, 2009, and listed on September 2, 2020, is located in Chengdu, Sichuan Province. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The main revenue composition of Yuandong Biopharmaceuticals includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Group 2 - According to data from the top ten holdings of funds, Hongde Fund has a significant position in Yuandong Biopharmaceuticals, with its Hongde Medical Innovation Mixed Fund A (012481) holding 27,000 shares, unchanged from the previous period, accounting for 8.53% of the fund's net value, making it the second-largest holding [2] - The Hongde Medical Innovation Mixed Fund A (012481) was established on February 22, 2023, with a latest scale of 14.8031 million CNY. The fund has achieved a return of 41.8% this year, ranking 1877 out of 8155 in its category, and a return of 32.63% over the past year, ranking 2503 out of 8029 [2]

Group 1 - The core point of the news is that Yuan Dong Bio (688513.SH) reported a decline in institutional investor holdings in its third-quarter report for 2025, with a total of 8 institutional investors holding 11.02 million shares, representing 6.24% of the total share capital, a decrease of 5.43 percentage points from the previous quarter [1] Group 2 - In the public fund sector, there were 2 public funds that increased their holdings compared to the previous period, with an increase ratio of 0.12%. Additionally, 3 new public funds were disclosed this quarter, while 171 public funds were not disclosed compared to the previous quarter [2] Group 3 - Regarding social security funds, there was 1 social security fund that was not disclosed in the previous quarter, specifically the National Social Security Fund 111 Combination [3]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for its content [1] - The quarterly financial report has not been audited [2] - The net profit attributable to shareholders increased by 2.77% year-on-year, while the net profit excluding non-recurring gains and losses grew by 4.69% year-on-year [2] Financial Data - The report period refers to the three months from the beginning to the end of the quarter [2] - The company recognized a total of 13.2962 million yuan in stock incentive expenses from the beginning of the year to the end of the reporting period [2] - The company’s repurchase account held 2,179,346 shares, accounting for 1.23% of the total share capital of 176,532,256 shares as of the end of the reporting period [5] Shareholder Information - There are no changes in the borrowing or returning of shares by the top ten shareholders due to transfer and financing [6] - The report does not include any additional important information regarding the company's operational situation during the reporting period [6]

Core Insights - The company reported a revenue of 364,685,045.87 yuan for the third quarter of 2025, representing a year-on-year decline of 1.55% [1] - The net profit attributable to shareholders of the listed company was 83,590,556.58 yuan, showing a year-on-year increase of 18.52% [1] Financial Performance - Revenue for Q3 2025: 364.69 million yuan, down 1.55% year-on-year [1] - Net profit for Q3 2025: 83.59 million yuan, up 18.52% year-on-year [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) reported a slight decline in revenue for the first three quarters of 2025, while net profit showed a modest increase, indicating a mixed performance in the company's financial health [1] Financial Performance - The company achieved a revenue of 1.019 billion yuan for the first three quarters, representing a year-on-year decrease of 2% [1] - The net profit attributable to shareholders was 220 million yuan, reflecting a year-on-year increase of 1.45% [1] - The non-recurring net profit was 173 million yuan, which is a year-on-year growth of 3.10% [1] - Basic earnings per share stood at 1.25 yuan [1]